NAMS Forensic Analysis

Executive Summary

Analysis Date: 2025-12-09 | Current Price: $35.75

NewAmsterdam Pharma (NAMS) presents a compelling high-asymmetry short opportunity. The company is a single-asset, late-stage biotech whose current ~$4.05B valuation appears to price in near-certain success for its cardiovascular outcomes trial (CVOT), PREVAIL. This optimism is contradicted by the historical failure rate of the CETP inhibitor class, massive red flags from coordinated insider selling plans by the entire C-suite, and significant shareholder dilution via stock-based compensation.

While NAMS boasts a strong balance sheet with $756M in cash and marketable securities, the risk/reward at this valuation is heavily skewed to the downside ahead of the binary PREVAIL data readout expected no earlier than late 2026.

---

🔴 Recent Material Events (8-K Analysis)

• •EMA Marketing Application Validation (Aug 18, 2025): The European Medicines Agency (EMA) validated the Marketing Authorization Applications for obicetrapib. This is a positive development that officially begins the review process for potential approval in Europe, a key de-risking milestone for that market.
• •Director Resignation (Nov 5, 2025): Nicholas Downing resigned from the Board of Directors. The filing states the resignation was not due to any disagreement, making this a likely neutral event, though board turnover is always worth monitoring.

---

🔴 Insider Trading Activity

This is the most significant red flag. A coordinated wave of C-suite executives established 10b5-1 selling plans in September 2025, signaling a potential lack of long-term conviction or a desire to de-risk before the binary CVOT data.

• •CEO, Michael Davidson (Sep 29, 2025): Adopted a new plan to sell up to 750,000 shares.
• •COO, Douglas Kling (Sep 29, 2025): Adopted a plan to sell up to 594,573 shares.
• •CFO, Ian Somaiya (Sep 30, 2025): Adopted a plan to sell up to 200,000 shares.
• •CAO, Louise Kooij (Sep 23, 2025): Adopted a plan to sell up to 290,000 shares.

This synchronized move by top leadership to liquidate significant holdings is a strong negative signal about their view of the intrinsic value versus the current market price.

---

Current News & Market Context

The market narrative is almost entirely focused on the potential of obicetrapib as a convenient, oral add-on to statins for LDL-C reduction. The successful Phase 3 LDL-lowering trials and recent EMA filing have fueled bullish sentiment. However, the market appears to be under-appreciating the primary risk: the pending PREVAIL cardiovascular outcomes trial, which is the true determinant of the drug's commercial viability and has historically been the graveyard for this drug class.

---

Business Model Analysis

NAMS is a classic late-stage biotech with a single key asset, obicetrapib. Its current revenue is non-recurring and derived from a licensing partnership with Menarini for the European market. The future business model hinges on:

1. •PREVAIL CVOT Success: A positive outcome is required for broad market access and pricing power.
2. •Regulatory Approval: Gaining approval from the FDA and EMA.
3. •Commercial Execution: Successfully launching and competing in a crowded cardiovascular market.

Failure at any of these steps, particularly the CVOT, would render the business model unviable.

---

✅ Financial Health

NAMS's primary strength is its balance sheet. The company is well-capitalized to fund operations through the anticipated PREVAIL data readout.

---

⚠️ Valuation Analysis

At $35.75 per share, NAMS has a market capitalization of approximately $4.05B. This valuation seems stretched for a pre-commercial, single-asset company.

Reverse DCF Insights

To justify the current $4.05B valuation, the market is implicitly pricing in peak sales for obicetrapib of approximately $9.0B, assuming a 60% probability of success. This places it in the mega-blockbuster category, a heroic assumption given the competitive landscape and the historical failures of CETP inhibitors.

Price Context

The stock has appreciated significantly in 2025, with the price rising from ~$23 in March to over $35 today. This momentum appears driven by the positive LDL-lowering data, while ignoring the much larger binary risk of the CVOT.

---

Competitive Position

Obicetrapib aims to compete as an oral, once-daily therapy for patients who need additional LDL-C lowering on top of statins. The landscape is crowded:

• •Injectable PCSK9 Inhibitors: Highly effective (Amgen's Repatha, Sanofi/Regeneron's Praluent) but require injections.
• •Oral Non-Statins: Esperion's Nexletol/Nexlizet is an oral competitor, though less potent.
• •Generics: Statins are cheap and the first line of defense.

Obicetrapib's success depends entirely on the PREVAIL CVOT demonstrating a clear cardiovascular benefit that justifies its adoption and price.

---

🔴 Management Quality

While the management team has relevant experience, their credibility is severely undermined by the coordinated establishment of 10b5-1 selling plans across the entire C-suite. Actions speak louder than words, and this action suggests a belief that the stock is fully or over-valued, representing a major misalignment with long-term shareholders.

---

Risk Factors

• •🔴 Clinical Failure (High Severity): The PREVAIL CVOT is a binary event. Failure would be catastrophic, likely causing the stock to fall >80% to cash value.
• •⚠️ Valuation Risk (High Severity): The current valuation prices in a high degree of success, leaving little room for error and creating significant downside asymmetry.
• •⚠️ Commercial Risk (Medium Severity): Even with a positive CVOT, gaining market share and favorable reimbursement against entrenched competitors will be challenging.

---

Forensic Accounting Flags

• •🔴 Excessive Stock-Based Comp (SBC): SBC for the first nine months of 2025 was $45.4M, representing ~25% of total operating expenses. This is a massive non-cash expense that significantly dilutes shareholders.
• •🔴 Coordinated Insider Selling: As detailed above, the entire C-suite has filed plans to sell large amounts of stock. This is the most bearish indicator available.
• •⚠️ Shareholder Dilution Overhang: There are ~25.1M potential shares from outstanding options, RSUs, and warrants, representing over 22% of the current shares outstanding.

---

Short Thesis

The investment case for shorting NAMS is built on four pillars:

1. •Extreme Valuation: The ~$4.05B market cap is pricing in a near-perfect outcome for the PREVAIL CVOT and blockbuster sales, ignoring substantial risks.
2. •History of Class Failure: The CETP inhibitor drug class has a poor track record in CVOTs. The market is ignoring this adverse history.
3. •Damning Insider Signal: The coordinated insider selling plans from the CEO, CFO, COO, and CAO are a powerful signal that management believes the stock is at or near a peak.
4. •Binary Catalyst: The PREVAIL trial provides a clear, dateable catalyst that could lead to a rapid and severe price correction if the data is not overwhelmingly positive.

---

Catalysts & Timeline

• •Primary Bear Catalyst: PREVAIL CVOT Data Readout. The trial is event-driven. Earliest potential readout is late 2026, but could extend into 2027.
• •Interim Catalyst: EMA Decision on MAA. Expected around mid-2026. An approval could cause a short-term price spike, but the thesis rests on the CVOT.

---

Price Targets

---

Investment Recommendation

SHORT with High Conviction (8/10).

The current valuation offers a highly asymmetric risk/reward profile for a short position. The market is exhibiting extreme euphoria and ignoring clear fundamental risks and damning behavioral signals from management. The binary nature of the upcoming CVOT provides a clear catalyst for the thesis to play out.

---

One-Liner Thesis

NAMS is a single-asset company whose frothy valuation ignores the high historical failure rate of its drug class in cardiovascular outcome trials and the damning signal of coordinated insider selling by top executives.